In: Archives of Cardiovascular Diseases, 2017, vol. 110, no. 6, p. 389–394
Background: Transcarotid access is an alternative route for transcutaneous aortic valve implantation (TAVI) in patients with impossible transfemoral access.Aims: We evaluated the safety, effectiveness and early and late clinical outcomes of CoreValve® implantation via the common carotid artery.Methods: Eighteen patients (10 men, 8 women; mean age 84 ± 5 years) at high surgical risk (mean...
|
In: European Heart Journal, 2012, vol. 33, no. 23, p. 2992-2992
|
In: Open Heart, 2016, vol. 3, no. 1, p. e000373
Background Interventional cardiologists may be immune to stress, allowing them to perform complex percutaneous interventions under pressure.Objectives To assess heart rate (HR) variations as a surrogate marker of stress of interventional cardiologists during percutaneous cardiac procedures and in every-day life.Design This is a single-centre...
|
In: Swiss Medical Weekly, 2016, p. -
QUESTIONS UNDER STUDY: Head-to-head optical coherence tomography (OCT) data comparing metallic stents with bioresorbable vascular scaffolds (BVS) are lacking. This study assessed vascular healing at 9-month follow-up after implantation of everolimus- and biolimus-eluting stents (EES BES) and everolimus-eluting BVS.METHODS: OCT was performed in 74 patients enrolled in the EVERBIO II (NCT01711931)...
|
In: Trials, 2014, vol. 15, no. 1, p. 9
Background: Second-generation everolimus-eluting stents (EES) and third generation biolimus-eluting stents (BES) have been shown to be superior to first-generation paclitaxel-eluting stents (PES) and second-generation sirolimus-eluting stents (SES). However, neointimal proliferation and very late stent thrombosis is still an unresolved issue of drug-eluting stent (DES) implantation overall. The...
|
In: Archives of Cardiovascular Diseases, 2012, vol. 105, no. 11, p. 587–592
Objectifs Le but de cette étude est de comparer l’effet sur l’agrégation plaquettaire de la molécule originale de clopidogrel (clopidogrel bisulfate [Plavix®]) aux molécules génériques (clopidogrel besylate [clopidogrel Sandoz®] et clopidogrel hydrochloride [clopidogrel-Mepha®]) et au prasugrel (Efient®). Historique On suspecte que le sel utilisé pour lier la molécule de...
|
In: European Heart Journal, 2012, vol. 33, no. 23, p. 2292
|
In: Cardiovascular Medicine, 2012, vol. 15, no. 7-8, p. 228-229
|